China SXT Pharmaceuticals Inc
For the period ended Jan 23, 2025. Filed Jan 23, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jan 23, 2025 · Filed Jan 23, 2025
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
6-K 1 ea0228210-6k_chinasxt.htm REPORT OF FOREIGN PRIVATE ISSUER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2025
Commission File Number: 001-38773
CHINA SXT PHARMACEUTICALS, INC.
(Translation of registrant’s name into English)
178 Taidong Rd North, Taizhou
Jiangsu, China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F☒ Form 40-F☐
Resignation of Director
On January 20, 2025, Songfan He resigned from his positions as an independent director of the board of directors (the “Board”) of China SXT Pharmaceuticals, Inc. (the “Company”), the chairman of the
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.